About the Study

Chikungunya is an illness caused by a virus that spreads through mosquito bites, similar to other mosquito-spread illnesses like Zika, malaria, dengue, and West Nile Virus. If you are bit by an infected mosquito with chikungunya, you will develop symptoms in 3-7 days. The most common symptoms of infection are fever and joint pain. Others also experienced headaches, muscle pain, joint swelling or a rash. While the disease does not frequently result in death, many of the symptoms can be severe or disabling for several months or years after symptoms develop.

Currently, there is no vaccine to prevent or medicine to treat chikungunya virus infection.

While mosquitoes infected with Chikungunya today are more prevalent in countries in Africa, Asia, Europe, and the Indian and Pacific oceans, there is a risk that the virus will be imported to new areas by infected travelers. In 2014, the first chikungunya virus disease cases were reported among US travelers returning from affected areas and local transmission was identified especially in Florida, Puerto Rico, and the US Virgin Islands.

Rochester Clinical Research is participating in a study evaluating the immune response of a single dose of the study Chikungunya vaccine in healthy adults and adolescents between the ages of 18 and 64 years old. There is a 14% chance of placebo in this study. The study will last approximately 6 months with 6 visits to our office. Compensation is available up to $650 for time and travel, for those who qualify.


  • Be between the ages of 18 and 64 years old
  • Be in general good health
  • *Please note, other conditions apply